Dr Reddy's Voluntarily Recalls Six Drug Lots in US Over Potency Concerns

In a recent announcement, Dr. Reddy's Laboratories disclosed a voluntary recall of six lots of a medication designed to lower blood phenylalanine (Phe) levels, citing subpotency issues. The Hyderabad-based pharmaceutical giant is pulling back specific lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg from the consumer market. This decision comes after the discovery of powder discoloration in some packets, which has been linked to decreased potency of the product.

Representative image

The issue was identified through accelerated stability testing and bolstered by customer complaints. Dr. Reddy's Laboratories emphasized the potential health risks associated with the reduced efficacy of the product, including elevated Phe levels in patients. For infants and children, chronically high Phe levels can lead to severe neurocognitive consequences, such as irreversible intellectual disability, developmental delays, and seizures.

Dr. Reddy's Laboratories Inc., the US subsidiary of the company, has confirmed that there have been no reports of adverse events related to this recall as of now. The firm is actively communicating with its distributors and customers through recall notification letters and is coordinating the return of all affected products. The company advises anyone with an inventory of the recalled product to inspect their stock and immediately quarantine any of the identified lots.

Consumers in possession of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg from the recalled lots are urged to return the product to their place of purchase. This proactive measure by Dr. Reddy's Laboratories underscores their commitment to patient safety and adherence to quality standards.